Coya CFO granted 140,041 stock options at $4.73

Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of stock options on January 22, 2026.

Rhea-AI Filing Summary

Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of stock options on January 22, 2026. The award covers 140,041 stock options, each giving the right to buy one share of common stock at an exercise price of $4.73 per share.

The options vest in monthly installments over 36 months, as long as the executive continues to serve through each vesting date. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

Insider Trade Summary

Grant/Award: 140,041 shares

Grant/Award 1 txn

Insider SNYDER DAVID S

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	140,041	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 140,041 contracts (Direct)

Footnotes (1)

1. F1. Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Coya Therapeutics (COYA) report for its CFO?

Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of 140,041 stock options on January 22, 2026.

What is the exercise price of the CFO stock options at Coya Therapeutics (COYA)?

The stock options granted to the CFO have an exercise price of $4.73 per share for Coya Therapeutics common stock.

How do the newly granted Coya Therapeutics (COYA) CFO options vest?

The shares underlying the option vest in monthly installments over 36 months, subject to the CFO’s continuous service through each vesting date.

What happens to the CFO’s Coya Therapeutics (COYA) options if there is a change in control?

Upon a change in control of Coya Therapeutics, the shares underlying the option will fully vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan.

How many Coya Therapeutics (COYA) derivative securities does the CFO hold after this transaction?

Following this transaction, the CFO beneficially owns 140,041 stock options, held as direct ownership.

Under which plan were the Coya Therapeutics (COYA) CFO options granted?

The options were granted pursuant to Coya Therapeutics’ 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 08:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SNYDER DAVID S

(Last) (First) (Middle)

5850 SAN FELIPE ST., SUITE 500

(Street)

HOUSTON TX 77057

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coya Therapeutics, Inc. [ COYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.73	01/22/2026		A		140,041		(1)	01/22/2036	Common Stock, par value $0.0001 per share	140,041	$0	140,041	D

Explanation of Responses:

1. Subject to continuous service through each vesting date, the shares underlying the option will vest in monthly installments over the next 36 months. Upon a change in control of the Issuer, the shares underlying the option will vest and the option will become immediately exercisable pursuant to the Issuer's 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.

	/s/ David Snyder, Attorney-in-Fact	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.